Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Johnson and Johnson
McKesson
AstraZeneca
Mallinckrodt

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

LIPIODOL Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Lipiodol, and when can generic versions of Lipiodol launch?

Lipiodol is a drug marketed by Guerbet and is included in one NDA.

The generic ingredient in LIPIODOL is ethiodized oil. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ethiodized oil profile page.

Drug patent expirations by year for LIPIODOL
Drug Prices for LIPIODOL

See drug prices for LIPIODOL

Generic Entry Opportunity Date for LIPIODOL
Generic Entry Date for LIPIODOL*:
Constraining patent/regulatory exclusivity:
SELECTIVE HEPATIC INTRA-ARTERIAL USE FOR IMAGING TUMORS IN ADULTS WITH KNOWN HEPATOCELLULAR CARCINOMA (HCC)
NDA:
Dosage:
OIL;INTRALYMPHATIC, INTRAUTERINE

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LIPIODOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assiut UniversityEarly Phase 1
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 1
University Hospital, Strasbourg, FrancePhase 4

See all LIPIODOL clinical trials

US Patents and Regulatory Information for LIPIODOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Guerbet LIPIODOL ethiodized oil OIL;INTRALYMPHATIC, INTRAUTERINE 009190-001 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Express Scripts
Moodys
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.